Electromed (ELMD) Q3 2025 Earnings Call May 13, 2025 05:00 PM ET Speaker0 Greetings, and welcome to the Electromed Third Quarter Fiscal twenty twenty five Earnings Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. It is now my pleasure to introduce you to your host, Mike Kavanaugh, Investor Relations. Thank you, Mike. You may begin. Speaker1 Good afternoon, and thank you for joi ...

DoubleDown Interactive Co. (DDI) Q1 2025 Earnings Call May 13, 2025 05:00 PM ET Speaker0 Good afternoon, and welcome to Double Down Interactive Earnings Conference Call for the First Quarter Ended 03/31/2025. My name is Michelle, I will be your operator this afternoon. Prior to this call, Double Down issued its financial results for the first quarter of twenty twenty five in a press release, a copy of which is available in the Investor Relations section of the company's website at www.doubledowninteractive. ...

CVD Equipment (CVV) Q1 2025 Earnings Call May 13, 2025 05:00 PM ET Speaker0 Greetings and thank you for standing by and welcome to the CVD Equipment Corporation's First Quarter twenty twenty five Earnings Call. As a reminder, this conference is being recorded. We will begin with some prepared remarks followed by a question and answer session. Presenting on the call today will be Emmanuel Lakios, President and CEO and member of the CVD Board of Directors and Richard Catalano, Executive Vice President and Chi ...

CarParts.com (PRTS) Q1 2025 Earnings Call May 13, 2025 05:00 PM ET Speaker0 Good afternoon. At this time, all participants will be in listen only mode. Please note this call is being recorded. I would now like to pass the conference over to our host, Ryan Lockwood, Chief Financial Officer. Please go ahead. Speaker1 Hello, everyone, and thank you for joining us for the CarParts.com First Quarter 20 20 5 Conference Call. Joining me today is David Mignon, Chief Executive Officer. Before I turn it over to David ...

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was approximately $300,000, compared to $160,000 in the same period last year, representing an increase of 87.5% [16] - Operating expenses for Q1 were $4,700,000, up from $3,300,000 a year ago and down from $4,900,000 in the previous quarter [16] - Net loss for the quarter was $4,300,000, compared to a net loss of $3,100,000 for the same period last year [16] - Adjusted EBITDA loss was $3,900,000 for Q1, compared to a loss of $2,400,000 for the same period last year [18] - Remaining performance obligation (RPO) was $13,850,000, a decrease of $410,000 from the prior quarter but an increase from $4,030,000 a year ago [17] Business Line Data and Key Metrics Changes - The company is focusing on large enterprise deals and partnerships, with significant progress reported in contract negotiations with Fortune 500 companies [8][10] - A paid live production trial agreement was signed with a global Fortune 100 retailer, indicating a move towards long-term contracts [10] - The company is also in the final stages of contract negotiations with a major identity fraud platform [10] Market Data and Key Metrics Changes - The company reported generating $13,000,000 in new pipeline in Q1, with expectations to build on this in Q2 [46] - The demand for biometric solutions is increasing, particularly due to rising concerns over cyber attacks and fraud [6][7] Company Strategy and Development Direction - The company aims to become a leader in the biometric authentication market, focusing on speed, accuracy, privacy, and interoperability [12][13] - Strategic investments have been made in privacy key technology, allowing biometric authentication without storing biometric data [12] - The company is expanding into public sector opportunities and smart city projects in South America and India [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving the $18,000,000 bookings target for 2025, despite delays in the sales process [19][16] - The macroeconomic environment is seen as dynamic, with potential for increased demand for biometric solutions due to rising fraud [6][7] Other Important Information - The company completed two capital raises in April and May, securing nearly $9,000,000 to improve its balance sheet and broaden its investor base [15] - The company received recognition as the best ID management platform in 2025 by FinTech Breakthrough Awards [14] Q&A Session Summary Question: When will the company start seeing leverage from partnerships? - Management indicated that they are already benefiting from partnerships and expect bookings to follow as they invest in channel partners [25][26] Question: Why are expenses high compared to revenue? - Management explained that current expenses are driven by investments in headcount for sales and R&D, which are necessary for future growth [29][30] Question: How many Fortune 500 clients are needed to meet the $18,000,000 goal? - Management stated that signing four to five large deals could potentially meet the target, with some deals large enough to cover the entire amount [36][37][40]

Financial Data and Key Metrics Changes - As of March 31, 2025, the company had $335.5 million in cash, cash equivalents, and investments [29] - Research and development expenses for Q1 2025 were $50.2 million, including $5 million in non-cash stock-based compensation [29] - General and administrative expenses for Q1 2025 were $15 million, including $7.1 million in non-cash stock-based compensation [29] - The net loss for Q1 2025 was $59.7 million, or $0.28 per share, including $12.2 million in non-cash stock-based compensation [29] - Updated guidance for 2025 indicates an expected cash burn of approximately $150 million, with full-year GAAP operating expenses projected at approximately $230 million [29] Business Line Data and Key Metrics Changes - The ALPHA-three trial has seen over 250 patients consented for MRD screening, with nearly half in the last three months, indicating improved site engagement [9][20] - ALLO-three sixteen is showing signs of efficacy in heavily pretreated advanced renal cell carcinoma, with a 50% best overall response rate in patients expressing high levels of CD70 [24] - ALLO-three 29 is set to launch the RESOLUTION trial mid-2025, aiming to change treatment for autoimmune diseases by potentially eliminating lymphodepletion [11][25] Market Data and Key Metrics Changes - Nearly 50 activated US sites are involved in the ALPHA-three trial, with plans for international expansion starting in Canada [21] - The company is experiencing strong enthusiasm from investigators, which is translating into increased patient screening activity [20][21] Company Strategy and Development Direction - The company is focused on making CAR T therapies more accessible through an allogeneic approach, with a strategy launched in January 2024 aimed at redefining cell therapy [6][13] - The company is prioritizing cash runway preservation, extending it into the second half of 2027, while driving forward with promising clinical trials [12][28] - The company is adapting its operational strategy to address macroeconomic challenges and enhance trial execution [12][28] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the evolving regulatory landscape and expresses confidence in the FDA's commitment to scientific integrity and patient-centered outcomes [14][15] - The company believes that strong science and meaningful clinical benefits will continue to prevail in the regulatory environment [16] - Management is optimistic about the potential of their allogeneic CAR T programs to reshape treatment paradigms in hematologic malignancies and solid tumors [27] Other Important Information - The company is making targeted reductions in manufacturing operations to achieve cost savings while maintaining core capabilities [28] - The ALLO-three sixteen data will be presented at ASCO on June 1, which is expected to be significant for the field [22] Q&A Session Summary Question: Progress of enrollment in the first line study and logistical issues - Management explained that site-related issues caused a 3-4 month delay in patient screening, but recent improvements in site engagement are translating into increased screening activity [35][36] Question: Differences in site-related factors between community and academic sites - Management indicated that there is no significant difference in the occurrence of site-related factors between community and academic sites, with both showing encouraging activity once operational [40][46] Question: Regulatory implications of expanding to international sites - Management stated that the global standard for frontline DLBCL treatment remains consistent, and the expansion is not expected to introduce significant heterogeneity [65] Question: Potential partnership for autoimmune programs - Management expressed willingness to partner on autoimmune programs to de-risk them, especially given the current market environment [68] Question: Expected data size for ALLO-three 29 - Management indicated that the expected data size for the initial readout will be limited due to the nature of the dose escalation study, but they are focused on ensuring robust data collection [75] Question: Overlap of site-related challenges in ex-US sites - Management believes that ex-US sites will be better equipped due to the integrated care model typically found in those regions [96]

Zevra Therapeutics (ZVRA) Q1 2025 Earnings Call May 13, 2025 04:30 PM ET Company Participants Nichol Ochsner - Vice President of Investor Relations & Corporate CommunicationsNeil McFarlane - President & CEOJoshua Schafer - CCOR. LaDuane Clifton - CFO, Secretary & TreasurerSumant Kulkarni - Managing DirectorJason Butler - Managing Director & Biotechnology Equity ResearchEddie Hickman - Vice President Conference Call Participants Lachlan Hanbury-Brown - Biotech Equity Research Analyst Operator Good afternoon ...

WhiteHorse Finance (WHF) Q1 2025 Earnings Call May 13, 2025 04:30 PM ET Company Participants Robert Brinberg - PresidentStuart Aronson - CEO & DirectorJoyson Thomas - CFO & Principal Accounting OfficerMelissa Wedel - Vice President, U.S. Equities ResearchRobert Dodd - Director - Finance Operator Good afternoon. My name is Margo, and I'll be your conference operator today. At this time, I'd like to welcome everyone to the WhiteHorse Finance First Quarter twenty twenty five Earnings Conference Call. Our hosts ...

Financial Data and Key Metrics Changes - The company reported a net loss of $22 million in the quarter compared to a net income of $6.2 million in the prior year, driven by higher general and administrative expenses and marketing costs [13] - Adjusted EBITDA was $4.1 million in the quarter, down from $22.2 million in the same quarter of the previous year [26] - Revenue grew 5.3% on a constant currency basis, but reported revenue was roughly flat year over year [12] Business Line Data and Key Metrics Changes - Paid content revenue grew 2.8% on a constant currency basis year over year, driven by strength in Japan, offset by declines in Korea and the rest of the world [17] - Advertising revenue increased by 13.6% on a constant currency basis, with strong performance in Korea and Japan, but a decline in the rest of the world [18] - IP Adaptation revenue saw a 20.7% increase year over year on a constant currency basis, with significant growth in Japan [19] Market Data and Key Metrics Changes - In Korea, revenue grew 3.6% year over year on a constant currency basis, primarily driven by advertising and IP adaptations [20] - Japan posted revenue growth of 9.4% on a constant currency basis, with all revenue streams contributing positively [22] - The rest of the world experienced a revenue decline of 4% year over year on a constant currency basis [24] Company Strategy and Development Direction - The company is focused on building a local creator ecosystem in Japan and expanding its cross-border strategy by taking Japanese content to other markets [6] - Investments are being made in the English language platform to enhance user experience and engagement [7][10] - The company aims to leverage its flywheel of creators, content, and users to generate profitable growth over the long term [31] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the resilience of the business model despite potential market downturns, citing a low average revenue per paying user [10] - The company anticipates revenue growth in the range of 2.2% to 5.2% for the second quarter of 2025 [29] - Management is closely monitoring market health and believes in the long-term growth potential of newer markets [35] Other Important Information - The company faced challenges with a security upgrade affecting search engine indexing, which contributed to a decline in web MAU [14] - The gross profit for the quarter was $71.6 million, resulting in a gross margin of 22%, down from 25.2% in the prior year [25] - The company is making significant changes to its English language web comic app to improve user engagement [60] Q&A Session Summary Question: User growth initiatives and investment cadence - Management highlighted strong long-term growth signs in newer markets, particularly a 19% increase in English-speaking platform MAU [35] Question: Importance of local content in local markets - Management emphasized the significance of local creator IP and partnerships to enhance global reach and engagement [39] Question: MAU decline in Korea and future growth potential - Management noted that while Korea has high penetration, constant currency revenue growth of 3.6% indicates potential for future growth [46] Question: Update on advertising revenue in North America - Management stated that North America advertising is still in early stages, with a focus on building foundational products for future growth [49] Question: Impact of global franchises on monetization - Management clarified that global franchises have historically contributed positively to the core paid content margin structure [53] Question: Security update on Wattpad and user impact - Management confirmed that Wattpad's issues significantly impacted total MAU declines, but it is not a major contributor to paid content revenue [66] Question: Engagement levels of licensed IP in the U.S. - Management indicated that engagement levels depend on the specific IP, but there is potential for licensed IP to drive user engagement [85]

Vaxart (VXRT) Q1 2025 Earnings Call May 13, 2025 04:30 PM ET Company Participants Edward Berg - Senior Vice President and General CounselSteven Lo - CEO , President & DirectorJames Cummings - Chief Medical OfficerSean Tucker - Founder & Chief Scientific OfficerPhillip Lee - Chief Financial OfficerCheng Li - Director - Equity ResearchMayank Mamtani - Senior Managing Director & Group Head of HealthcareLiang Cheng - Senior Research Associate Operator Greetings. Welcome to Vaxart Business Update and First Quart ...